Dariohealth CORP

DarioHealth Corp. announced the pricing of a registered direct offering, raising approximately $23.5 million through the sale of common stock and pre-funded warrants.

DarioHealth Corp. announced on July 10, 2026, that the medical leave of absence for Steven Nelson, President and Chief Commercial Officer, has been extended indefinitely, with his duties temporarily reassigned.

DarioHealth Corp. announced the appointment of John R. Palumbo to its Board of Directors, leveraging his extensive healthcare operating experience to support the company's commercial scaling.

DarioHealth Corp. has amended its Certificate of Incorporation to explicitly grant its Board of Directors the power to alter and repeal company bylaws, a change approved by stockholders.

DarioHealth Corp. stockholders approved the election of directors, auditor ratification, preferred share conversions, Twill acquisition share issuances, and an increase in the equity incentive plan at their 2026 Annual Meeting.

DarioHealth Corp. has amended its credit agreement with Callodine Commercial Finance, resetting financial covenants, adjusting liquidity requirements, and modifying warrant terms.

DarioHealth Corp. reported a 17.3% decrease in revenue for the first quarter of 2026 compared to the prior year, primarily due to a non-recurring pharmaceutical partner revenue in the previous period.

DarioHealth Corp. reported a 32.5% revenue decrease in Q3 2025, alongside a reduced net loss and an ongoing strategic review to maximize shareholder value.

DarioHealth Corp. refinanced its debt facility and reduced operating expenses in Q2 2025, but reported increased net losses attributable to common shareholders and faces substantial doubt about its ability to continue as a going concern.

DarioHealth Corp. announces a 17.3% increase in revenue for Q1 2025, driven by commercial channel growth, alongside strategic debt refinancing and new partnerships aimed at expanding its B2B2C strategy.

DarioHealth Corp. saw a significant increase in revenue for Q3 2024, driven by growth in its commercial channel and the acquisition of Twill, despite ongoing losses and concerns about its ability to continue as a going concern.

DarioHealth Corp.'s Q2 2024 results show a mixed picture with revenue growth offset by increased expenses and a significant workforce reduction, alongside the integration of Twill.

DarioHealth Corp. reported a decrease in 2025 revenues and continued net losses, alongside significant operational efficiency gains and customer growth, while initiating a strategic review to maximize shareholder value.

DarioHealth Corp. released its 10-K filing, summarizing its financial performance for the year ended December 31, 2024, and detailing its strategic initiatives for future growth in the digital health market.

DarioHealth Corp. has finalized a share exchange agreement and amended existing contracts, signaling a move to simplify its capital structure and enhance operational efficiency.

Dennis Matheis, a Director of DarioHealth Corp., purchased 14,430 shares of common stock on August 12, 2024 for $6.93 per share.

DarioHealth Corp.'s President and CCO, Steven Charles Nelson, acquired 30,000 shares of common stock as a restricted award, increasing his beneficial ownership to 34,750 shares.

DarioHealth Corp. Director Adam K. Stern received an award of 20,000 restricted common shares, vesting in two years.

DarioHealth Corp. Director Lawrence B. Leisure was granted 20,000 restricted shares of common stock, vesting two years from the grant date, following a recent 20-for-1 reverse stock split.

DarioHealth Corp. Director Yoav Shaked reported the acquisition of 20,000 shares of common stock on September 11, 2025, as a restricted share award.

DarioHealth Corp.'s CEO, Erez Raphael, received a restricted share award of 60,000 common shares following a 20-for-1 reverse stock split.

DarioHealth Corp. calls its Annual Meeting for January 29, 2026, to vote on director re-elections, auditor ratification, prior equity issuances, an expanded incentive plan, executive compensation, and a charter amendment.

DarioHealth Corp. is calling its annual meeting to vote on critical proposals including a reverse stock split to maintain Nasdaq listing, a significant increase in authorized shares for future capital needs, and amendments to its equity compensation plan.

DarioHealth Corp. is seeking stockholder approval for the conversion of preferred stock, issuance of common stock, and amendments to warrants and loan agreements with Avenue Venture Opportunities Fund.

DarioHealth Corp. will hold its annual stockholders meeting on December 18, 2024, to vote on the re-election of directors and the ratification of its independent auditor.

DarioHealth Corp. is holding a special meeting of stockholders on June 25, 2024, to vote on proposals related to share issuance following the acquisition of Twill Inc. and an amendment to the company's equity incentive plan.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 9.99% beneficial ownership stake in DarioHealth Corp. as of December 31, 2025.

Craig Kallman 2015 Living Trust and Craig Kallman report a 9.99% passive beneficial ownership in DarioHealth Corp. common stock.

Nantahala Capital Management, LLC and its managing members disclosed a 9.99% beneficial ownership stake in DarioHealth Corp. common stock.

Nantahala Capital Partners Limited Partnership has amended its Schedule 13G filing, reporting a beneficial ownership of 4.5912% in DarioHealth Corp., down from a previous stake above 5%.

Tasso Partners, LLC and Dana Carrera have filed an amended Schedule 13G, reporting a combined beneficial ownership of 9.99% in DarioHealth Corp. common stock and pre-funded warrants.

Titan Trust 2024 I has reported the complete disposition of its 2.5 million pre-split shares in DarioHealth Corp. during Q3 2025.